Switzerland’s Roche Holdings entered a merger agreement on November 26, 2024, to acquire U.S.-based Poseida Therapeutics, Inc. (PSTX) in a cash deal worth $1.5 billion.
As part of the deal, Roche will commence a tender offer to acquire all of Poseida’s outstanding shares for a price of $9.00 per share in cash at closing, representing a 214.69% premium from the stock’s last close.